Cutaneous adverse events in patients receiving anticancer therapy in a tertiary hospital setting: the old and the new

摘要

Background Targeted therapies and immunotherapies are increasingly prescribed, but classic chemotherapy agents are still highly used in cancer treatment. Both therapies, the old and the new, are associated with cutaneous adverse events (CAEs) that can cause treatment interruptions or reduce the quality of life of patients.